Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to 67983.33%.

  • 4D Molecular Therapeutics' EBITDA Margin rose 16364166700.0% to 67983.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 191982.5%, marking a year-over-year increase of 7984645600.0%. This contributed to the annual value of 507678.38% for FY2024, which is 5071337300.0% down from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' EBITDA Margin stood at 67983.33%, which was up 16364166700.0% from 396373.33% recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year EBITDA Margin high stood at 192905.26% for Q4 2023, and its period low was 5611700.0% during Q4 2024.
  • For the 5-year period, 4D Molecular Therapeutics' EBITDA Margin averaged around 475592.34%, with its median value being 13446.03% (2023).
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by 2000000000bps in 2024, then soared by 2000000000bps in 2025.
  • 4D Molecular Therapeutics' EBITDA Margin (Quarter) stood at 26917.39% in 2021, then surged by 91bps to 2303.13% in 2022, then surged by 8476bps to 192905.26% in 2023, then tumbled by -3009bps to 5611700.0% in 2024, then soared by 99bps to 67983.33% in 2025.
  • Its EBITDA Margin stands at 67983.33% for Q3 2025, versus 396373.33% for Q2 2025 and 383007.14% for Q1 2025.